Apremilast

Among small-molecule drugs, upadacitinib and deucravacitinib demonstrate the best efficacy for treatment of psoriatic arthritis, according to data published in Therapeutic Advances in Musculoskeletal Disease.

The second round of Medicare Part D price negotiations will feature two drugs familiar to rheumatologists — Ofev and Otezla — a move applauded by experts as they await the impact of the first-round of discounts anticipated next year.

CMS has selected 15 new drugs for the next round of Medicare Part D price negotiations, according to a press release from HHS.

Hand and whole body MRI can objectively measure improvements in joint and enthesis inflammation resulting from apremilast treatment for psoriatic arthritis, according to data published in The Lancet Rheumatology.

Ethan Craig, MD, spoke with Healio about treatment options currently available in psoriatic arthritis.

Treatment with apremilast led to improved clinical and patient-reported outcomes in early oligoarticular psoriatic arthritis at 16 weeks, according to data published in Annals of the Rheumatic Diseases.

In this Healio exclusive video, Raj Chovatiya, MD, PhD, discussed research into psoriasis from the American Academy of Dermatology Annual Meeting, examining results from the SPROUT study.

In this Healio exclusive video, Raj Chovatiya, MD, PhD, discussed research into the oral molecule apremilast from the Maui Derm 2024 meeting, examining the SPROUT study into apremilast’s use treating psoriasis.

Pediatric patients with psoriasis experienced significant improvement with oral apremilast treatment, according to phase 3 trial results.

SAN DIEGO — Apremilast is superior to placebo regarding joint response and disease control in patients with early oligoarticular psoriatic arthritis, according to data presented at ACR Convergence 2023.